Anti-histamine-succinyl-glycine binding domain (Anti-HSG) (Anti-HSG)

The anti-histamine-succinyl-glycine (anti-HSG) domain is a high-affinity antibody fragment, typically a single-chain variable fragment (scFv) derived from the murine 679 monoclonal antibody or its humanized version, h679. It serves as a critical component in pretargeting bispecific monoclonal antibody (bsAb) systems, particularly those utilizing the Dock-and-Lock (DNL) platform (Sharkey et al., 2003). In this therapeutic strategy, the anti-HSG domain acts as a synthetic receptor that is localized to tumor sites by the other arm of the bispecific antibody, which targets specific tumor-associated antigens like CEA or MUC1. Once the bispecific antibody has cleared from the blood, a small HSG-conjugated hapten carrying a payload, such as IMP288, is administered and binds rapidly to the anti-HSG domain (Schoffelen et al., 2014). This mechanism allows for high-contrast imaging and potent radiotherapy while minimizing the exposure of healthy tissues to radiation or toxic drugs. The anti-HSG domain has been extensively studied in clinical trials for the treatment and imaging of various cancers, including colorectal and pancreatic malignancies (Goldenberg et al., 2012). Its primary advantage lies in decoupling the slow-clearing antibody targeting step from the fast-clearing therapeutic delivery step.

Other names

679 antibody domainh679Anti-HSG scFvHistamine-succinyl-glycine capture domainAnti-HSG hapten-binding site

The anti-HSG domain functions as a high-affinity capture site in a two-step pretargeting system. A bispecific antibody (bsAb) is first administered to bind a tumor-associated antigen (e.g., CEA) and provide a localized anti-HSG binding site. After the bsAb clears from the circulation, a small HSG-labeled hapten carrying a diagnostic or therapeutic payload is administered, which is then rapidly captured by the anti-HSG domain at the tumor site (Goldenberg et al., 2012; Sharkey et al., 2003).